Kisspeptin: what the research shows
- By Reed Calder
- Last reviewed Nov 14, 2026
- 53 studies and official documents checked
In short
Kisspeptin is a hormone the brain makes to start the chain that makes sex hormones: it tells the hypothalamus to release GnRH, which tells the pituitary to release LH and FSH, which tell the testes or ovaries to make testosterone or estrogen. The piece used in most men’s testosterone studies, and the one the FDA lists for compounding, is kisspeptin-10, its shortest active piece. It isn’t an FDA-approved drug, and the FDA places kisspeptin-10 in its category of compounding ingredients that may present significant safety risks. Human trials are real but small and short, and most come from a few university groups in the UK and U.S. One injection or infusion raises LH within hours. Repeated dosing is where results split: twice-daily injections in women with absent periods lost most of their effect within two weeks, while 8-hour daily infusions in 7 healthy men kept LH up for 12 days. In 53 and 60 women having IVF, one kisspeptin-54 injection triggered egg maturation, but no trial has compared it with the standard trigger. For low sexual desire, two small trials changed brain scans, and in men a physical measure of arousal rose too. A trial of a kisspeptin drug candidate in 17 men with low testosterone was ended early for missing its main goal. Kisspeptin is on the World Anti-Doping Agency list for male athletes.
EvidenceCellAnimalHumanhuman trials of single doses and short infusions; no long-term data; cancer work is in cells
You’ll often read that kisspeptin boosts testosterone naturally, raises libido, restores fertility, stops cancer from spreading and has no side effects. This page covers what kisspeptin is, what each study used, how men, women and IVF patients responded, how the response fades with repeated doses, safety, and where it stands legally and in sport.
Names and forms you’ll see
| Name | What it is | Studied in people? |
|---|---|---|
| Kisspeptin, KISS1 peptides, metastin | A family of peptides made from the KISS1 gene. The gene was found in 1996 because it stopped melanoma cells from spreading, which is why the peptide was first called metastin (Lee et al., 1996; Clarke et al., 2015) | Yes |
| Kisspeptin-54, KP-54 | The longest active form and the main one in human blood, 54 amino acids (Clarke et al., 2015) | Yes: most IVF and women’s trials, and the brain-scan trials |
| Kisspeptin-10, KP-10, kisspeptin 112-121, metastin 45-54, “kisspeptin 10” | The shortest piece with full activity, 10 amino acids (sequence YNWNSFGLRF). It is the form the FDA lists for compounding and the one analyzed in a 2024 test of a black-market vial (PubChem CID 25240297; FDA GSRS) | Yes: the men’s testosterone studies |
| Kisspeptin-14, kisspeptin-13 | Other short natural pieces of the same peptide (Clarke et al., 2015) | Not on their own in the trials we found |
| MVT-602, TAK-448, TAK-683 | Investigational lab-made versions of kisspeptin, built to last longer in the body than the natural peptide (Abbara et al., 2020; MacLean et al., 2014) | Yes: MVT-602 in women, TAK-448 in men and prostate cancer |
| Fezolinetant | A different drug. It blocks neurokinin B, a neighboring brain signal, and is FDA-approved for menopausal hot flashes. It is not kisspeptin (Koysombat et al., 2025) | Not covered on this page |
CAS numbers
A CAS number is a substance’s chemical registry number. Some “research” vials list it in place of a name. A different number usually means a different form, such as a salt, or a different substance. The number below is for kisspeptin-10, the form the FDA lists for compounding; kisspeptin-54 and the analogues have their own numbers.
| Form | CAS number | Registry record |
|---|---|---|
| Kisspeptin-10 (KP-10, metastin 45-54) | 374675-21-5 | PubChem |
What kisspeptin is
Kisspeptin is a neuropeptide: a signaling peptide made by nerve cells and encoded by the KISS1 gene. The body cuts one long precursor into several pieces, kisspeptin-54 and shorter pieces of 14, 13 and 10 amino acids (Clarke et al., 2015). Kisspeptin-10 weighs 1,302.4 g/mol (PubChem CID 25240297).
Its best-established job is in reproduction. Kisspeptin binds a receptor called KISS1R (also GPR54) on nerve cells in the hypothalamus and makes them release gonadotropin-releasing hormone (GnRH). GnRH tells the pituitary to release luteinizing hormone (LH) and follicle-stimulating hormone (FSH), and those tell the testes or ovaries to make testosterone or estrogen. People born with inactivating changes in the kisspeptin gene or its receptor are infertile (Clarke et al., 2015).
Natural kisspeptin leaves the blood fast: the half-life of kisspeptin-54 in men was about 27.6 minutes (Dhillo et al., 2005). That is why trials use infusions, repeated injections or longer-lasting analogues. Kisspeptin is not a testosterone replacement. It acts on the signal that tells the testes to work, and in the older men tested the testes responded less (Abbara et al., 2018; Ullah et al., 2019).
What has been studied
In men: testosterone and the hormones that control it
| Study | Who | What was used | What it found |
|---|---|---|---|
| Dhillo et al., 2005 | 6 healthy men; double-blind crossover | Kisspeptin-54 into a vein, 4 pmol/kg a minute for 90 minutes, or saline | LH 10.8 against 4.2 U/L, FSH 3.9 against 3.2 U/L, and testosterone 24.9 against 21.7 nmol/L at 180 minutes (all p under .001) |
| George et al., 2011 | Healthy men: 6 for single doses, 4 for each infusion | Kisspeptin-10 into a vein: single doses of 0.01 to 3.0 mcg/kg, and 22.5-hour infusions of 1.5 or 4 mcg/kg an hour | LH peaked at 1 mcg/kg (4.1 to 12.4 IU/L at 30 minutes); a 3 mcg/kg dose gave a smaller rise. The 4 mcg/kg-an-hour infusion raised testosterone from 16.6 to 24.0 nmol/L |
| George et al., 2013 | 5 men with type 2 diabetes and low testosterone, and 7 healthy men; proof-of-concept | Kisspeptin-10 into a vein: one 0.3 mcg/kg dose, then 4 mcg/kg an hour for 11 hours in 4 of the men | LH rose in both groups after the dose. During the infusion, testosterone in the diabetic men rose from 8.5 to 11.4 nmol/L (p = .002) |
| Abbara et al., 2018 | 5 healthy men aged about 59 and 5 aged about 29 | Kisspeptin-54 into a vein, 0.1, 0.3 or 1.0 nmol/kg an hour for 3 hours | The LH response was preserved in the older men, but their testosterone rises were smaller |
| Ullah et al., 2019 | Healthy men in three age groups | Kisspeptin-10 into a vein, 1 mcg/kg once | LH rose in every age group; testosterone rose significantly only in the youngest group |
| Yeung et al., 2026 | 15 healthy men across three experiments (7 in the 12-day one), with 12 more as controls; single-blind, placebo-controlled | Kisspeptin-10 under the skin by pump: 1.25 to 10 nmol/kg an hour for 8 hours; 180 nmol an hour nonstop for 5 days; 150 nmol an hour for 8 hours a day for 12 days | Single doses raised LH, FSH and testosterone in a dose-dependent way. After 5 days nonstop, testosterone stayed raised but LH and FSH were back to vehicle levels. With 8 hours a day for 12 days, LH rose by 1.68 on day 1 and still by 1.14 on day 12 (p = .003 against vehicle) |
| Naveed et al., 2026 | 3 healthy men | Kisspeptin-10 into a vein, 12.5 mcg/kg an hour for 24 hours | LH rose 5- to 8-fold within 12 to 20 hours, then fell 13 to 47% from its peak by the end of the infusion |
| MacLean et al., 2014 | 82 healthy men aged 50 or older on the analogue TAK-448 and 30 on placebo; then men with prostate cancer | TAK-448 under the skin: single doses; 0.01 to 1 mg a day for 14 days; in the cancer patients, a one-month depot injection | Single doses raised testosterone 1.3- to 2-fold within 48 hours. With 14 days of continuous dosing above 0.1 mg a day, testosterone fell below baseline by 60 hours and below the castration level by day 8. In 4 of 5 cancer patients on the 12 or 24 mg depot, it fell below 20 ng/dL. Mild adverse events in 26% of healthy subjects |
| NCT02381288 | 17 men with low testosterone; phase 2, run by Takeda | TAK-448 under the skin: 0.1 mcg daily, 0.3 mcg twice a week or 1 mcg weekly for about 6 weeks, or placebo | The sponsor ended the study because it did not meet its primary endpoint, a testosterone measure. No serious adverse events were listed. We found no journal paper |
| NCT02369796 | 15 people with hypogonadotropic hypogonadism; phase 2a, run by Takeda | TAK-448 under the skin, 0.1 to 3 mcg once or twice a week for 4 weeks | The sponsor ended the study because it did not achieve its primary efficacy objective. No serious adverse events were listed. We found no journal paper |
A single dose or a short infusion reliably raised LH, and in men testosterone followed. What fades is the response to nonstop exposure: LH was back to vehicle levels after 5 days of continuous infusion, and the analogue TAK-448 pushed testosterone down to castration levels when given continuously for 14 days. Two industry trials of that analogue in men with low testosterone or hypogonadism were ended early. We found no published trial that gave kisspeptin for weeks to men with low testosterone and measured how they felt.
EvidenceCellAnimalHumanhormone responses in small trials; no trial of weeks of use in men with low testosterone
In women: cycles, absent periods and PCOS
| Study | Who | What was used | What it found |
|---|---|---|---|
| Dhillo et al., 2007 | Healthy women with regular cycles; 8 women tested in each phase | Kisspeptin-54, one injection under the skin, 0.2 to 6.4 nmol/kg; 0.4 nmol/kg in each phase | LH rose in every phase, most in the preovulatory phase (+20.64 IU/L) and least in the early follicular phase (+0.12) |
| Jayasena et al., 2011 | 4 to 5 men or women per group | Kisspeptin-10 by vein, under the skin or by infusion | LH and FSH rose in men. In women in the early follicular phase nothing changed, even at 10 nmol/kg by vein or 32 nmol/kg under the skin; in the preovulatory phase LH and FSH rose |
| Jayasena et al., 2009 | 10 women with hypothalamic amenorrhea (absent periods); randomized, double-blind | Kisspeptin-54 under the skin, 6.4 nmol/kg twice a day for 2 weeks, or saline | On day 1 LH rose by 24.0 IU/L; by day 14 it rose by 2.5. LH pulsing and ultrasound showed no change, and the women stayed responsive to GnRH |
| Jayasena et al., 2010 | Women with hypothalamic amenorrhea; randomized | Kisspeptin-54 twice a day or twice a week; the twice-weekly group for 8 weeks, against saline | Twice-daily dosing led to complete tolerance, with the FSH response nearly gone by day 2. Twice weekly gave only partial tolerance, and hormones stayed above saline at 8 weeks. No adverse effects were observed |
| Jayasena et al., 2013 | 5 healthy women per arm; single-blind | Kisspeptin-54 under the skin, 6.4 nmol/kg twice a day on cycle days 7 to 14, or saline | Cycles continued in every woman, but were shorter (26.8 against 28.6 days) with an earlier LH peak |
| Jayasena et al., 2014 | 5 women with hypothalamic amenorrhea | Kisspeptin-54 by vein nonstop, 0.01 to 1.00 nmol/kg an hour, or vehicle | LH pulses rose from 1.6 to 5.0 per 8 hours at each woman’s best dose, and the best dose differed between women |
| Romero-Ruiz et al., 2019 | 12 women with polycystic ovary syndrome who were not ovulating, plus rat models; pilot | Kisspeptin-54 under the skin, 6.4 to 12.8 nmol/kg twice a day for 21 days | A small LH rise. Two women grew a follicle and ovulated, one grew a follicle without ovulating, one became desensitized and the rest showed no follicle response. Partly funded by a drug company |
| Millar et al., 2017 | 2 women with high prolactin and no periods; exploratory | Kisspeptin-10 into a vein, 1.5 mcg/kg an hour for 12 hours | LH, FSH, estradiol and testosterone rose |
| Mills et al., 2025 | Healthy men, healthy women and women with hypothalamic amenorrhea; randomized, double-blind crossover | Kisspeptin-54 as a nasal spray, 12.8 nmol/kg | LH rose above placebo in all three groups, by 3.1 IU/L in men, 1.0 in women and 4.3 in the amenorrhea group. No adverse events were reported |
EvidenceCellAnimalHumanshort studies in 2 to 12 women per group; response fades with twice-daily dosing
In women having IVF
| Study | Who | What was used | What it found |
|---|---|---|---|
| Jayasena et al., 2014 | 53 women having IVF after hormone stimulation; no comparison group | One injection of kisspeptin-54 under the skin, 1.6 to 12.8 nmol/kg (24 women each at 6.4 and 12.8) | Eggs matured at every dose. Fertilization and embryo transfer occurred in 92% (49 of 53); biochemical pregnancy 40% (21 of 53) and clinical pregnancy 23% (12 of 53) |
| Abbara et al., 2015 | 60 women at high risk of ovarian hyperstimulation syndrome (OHSS); phase 2, open-label, randomized to dose | One injection of kisspeptin-54, 3.2 to 12.8 nmol/kg | Eggs matured in 95%. Per transfer (51 women): biochemical pregnancy 63%, clinical pregnancy 53%, live birth 45%. No woman developed moderate, severe or critical OHSS |
| Abbara et al., 2017 | 62 women at high risk of OHSS; randomized, placebo-controlled, phase 2 | Kisspeptin-54 9.6 nmol/kg, then a second dose 10 hours later or saline | An egg yield of at least 60% in 21 of 31 (71%) with two doses against 14 of 31 (45%) with one (p = 0.042). Moderate OHSS in 0 against 1 |
| Abbara et al., 2020 | 9 healthy women, 6 with PCOS and 6 with hypothalamic amenorrhea | The analogue MVT-602, 0.01 or 0.03 nmol/kg, against kisspeptin-54, 9.6 nmol/kg | MVT-602 gave a similar LH rise to kisspeptin-54 but it peaked later (21.4 against 4.7 hours) and lasted longer |
| Abbara et al., 2024 | 24 healthy women (phase 1) and 75 women with light ovarian stimulation (phase 2a); randomized, placebo-controlled | MVT-602, one injection of 0.1 to 3 mcg; triptorelin 0.2 mg in 5 women; placebo in 5 | Safe and well tolerated, with a half-life of 1.3 to 2.2 hours. Ovulation within 5 days in 75 to 100% on MVT-602 (100% at 3 mcg), 100% on triptorelin and 60% on placebo |
In small trials, one kisspeptin-54 injection triggered egg maturation in women at high risk of OHSS, a complication of IVF. The authors of the 2017 trial say further studies are needed to compare kisspeptin-54 with the established triggers (Abbara et al., 2017), and we found no trial that did. The IVF program is registered as NCT01667406 (175 women, results posted).
EvidenceCellAnimalHumanegg maturation shown in small phase 2 trials; no comparison with standard triggers
In people: desire, mood and other effects
| Study | Who | What was used | What it found |
|---|---|---|---|
| Thurston et al., 2022 | 40 premenopausal women with low sexual desire (HSDD) randomized, 32 finished; double-masked crossover | Kisspeptin-54 into a vein, 1 nmol/kg an hour for 75 minutes, or placebo | Brain scans showed changes in areas that process sexual cues and attractive faces, and some changes tracked sexual distress and aversion. Well tolerated, with no adverse effects reported. The main measure was brain activity, not a desire score |
| Mills et al., 2023 | 37 men with HSDD randomized, 32 finished; double-blind crossover | The same 75-minute infusion, or placebo | Brain activity to sexual videos changed (effect size 0.81, p = .003), and penile response to sexual stimuli was up to 56% higher than on placebo (p = .02). “Happiness about sex” rose by 0.63 points (p = .02). The main measure was brain activity |
| Mills et al., 2025 | 95 healthy adults (63 men, 32 women); double-blind crossover | The same 75-minute infusion, or placebo | Anxiety scores didn’t change (p = .13), and neither did cortisol, blood pressure or heart rate |
| Yang et al., 2021 | 27 healthy men; double-blind crossover | The same infusion | No change in brain response to food images or in appetite ratings |
| Izzi-Engbeaya et al., 2018 | 15 healthy men | Kisspeptin into a vein, 1 nmol/kg an hour | Insulin release after a glucose load rose. Appetite, gut hormones and food intake didn’t change |
| Comninos et al., 2022 | 26 healthy men; double-blind crossover | Kisspeptin for 90 minutes, or placebo | Osteocalcin, a bone-building marker, rose by up to 20.3% (p = .021); bone-breakdown markers didn’t change |
| Galbiati et al., 2025; Galbiati et al., 2026 | 12 healthy adults, half of them women | Kisspeptin 112-121 into a vein, one 0.24 nmol/kg dose | Oxytocin rose 18.8% at 10 minutes (31.9% in men, 5.7% in women). Vasopressin didn’t change |
The two low-desire trials each gave one 75-minute infusion and measured brain scans first. A 2026 systematic review of peptides for male sexual dysfunction called kisspeptin promising but the evidence limited, with small samples and short follow-up, and another 2026 review said it “remains investigational” (Ramez et al., 2026; Vasylieva et al., 2026).
EvidenceCellAnimalHumansingle infusions in 12 to 95 people; brain scans are not symptom scores
In people: kisspeptin as a test
Kisspeptin has also been used to test the brain’s hormone signal. In 21 men with congenital hypogonadotropic hypogonadism, the LH rise after one injection was below 2.0 IU/L in every man, while all 21 healthy men rose above 4.0 (Abbara et al., 2021). In 16 children with delayed puberty, all 8 whose LH rose by 0.8 mIU/mL or more went on to enter puberty, and none of the 8 at 0.4 or below had by age 18 (Chan et al., 2020).
In rats: repeated dosing
| Study | Who | What was used | What it found |
|---|---|---|---|
| Ramzan et al., 2022 | Prepubertal male rats; saline-treated controls | Kisspeptin-10 into the abdomen twice a day at three doses (10 pg, 1 ng and 1 mcg) | Testosterone was lower than in controls at the 1 ng and 1 mcg doses, and the testosterone-making Leydig cells showed degeneration and other structural changes. One small study in young rats |
EvidenceCellAnimalHumanone study in young rats; no human study looked at testes tissue
In cells and tumors: cancer spread
| Study | What it covered | What it found |
|---|---|---|
| Lee et al., 1996 | Human melanoma cells | Adding chromosome 6 cut the cells’ spread by at least 95%. The KiSS-1 gene was active only in non-spreading cells, and adding the gene suppressed spread in an expression-dependent way |
| Shah et al., 2025 | Two triple-negative breast cancer cell lines in the lab | Kisspeptin-10 lowered cell survival and movement and shifted genes toward a less aggressive state. A lab-dish study |
| Wang et al., 2019 | 6 studies of 559 people with colorectal cancer; meta-analysis | Low KISS1 activity in the tumor went with a higher risk of poor outcome (hazard ratio 1.71). An association, not a treatment test |
| Gomaa et al., 2022 | 41 women with breast cancer | The kisspeptin receptor gene was more active in advanced and triple-negative tumors, and the authors say kisspeptin may not act as a metastasis suppressor in breast cancer |
We found no trial that gave kisspeptin to people to treat cancer or stop its spread. In the prostate cancer patients given the analogue TAK-448, the effects measured were lower testosterone and PSA (MacLean et al., 2014).
EvidenceCellAnimalHumancell and tumor-tissue studies only; no treatment trial in people
The usual claims, checked
| Claim | Verdict | What the studies found |
|---|---|---|
| Kisspeptin boosts testosterone | Mixed | A single dose or short infusion raised LH and testosterone in healthy men and in a few men with type 2 diabetes (Dhillo et al., 2005; George et al., 2011; George et al., 2013). Nonstop exposure fades: LH was back to vehicle levels after 5 days, and a continuous analogue lowered testosterone to castration levels (Yeung et al., 2026; MacLean et al., 2014). A trial of that analogue in men with low testosterone was stopped for missing its main goal (NCT02381288). In one rat study, twice-daily injections lowered testosterone (Ramzan et al., 2022) |
| It raises libido | Mixed | Two small single-infusion trials (32 women and 32 men finished) changed brain scans in people with low desire, and in men a penile arousal measure rose up to 56% over placebo (Thurston et al., 2022; Mills et al., 2023). Neither tested a repeated dose or measured desire over weeks, and 2026 reviews call the evidence limited (Ramez et al., 2026) |
| It restores fertility | Mixed | One injection triggered egg maturation in IVF, and kisspeptin raised LH in women with absent periods, but the effect faded with twice-daily dosing and only 2 of 12 women with PCOS ovulated in a pilot (Abbara et al., 2015; Jayasena et al., 2009; Romero-Ruiz et al., 2019). We found no trial of kisspeptin for infertility in men |
| A kisspeptin injection can trigger egg maturation in IVF | Supported | Yes, in small trials: eggs matured in 95% of 60 women at high risk of OHSS, and a randomized trial found more eggs with a second dose, 71% against 45% (p = 0.042) (Abbara et al., 2015; Abbara et al., 2017) |
| It is a better or safer IVF trigger than the standard one | Untested | We found no trial comparing kisspeptin with the standard trigger in IVF patients; the only comparison arm was 5 healthy women on a different drug (Abbara et al., 2017; Abbara et al., 2024) |
| It keeps working when used every day | Mixed | Studies disagree. Twice-daily injections in women with absent periods lost most of their LH effect within 2 weeks (24.0 to 2.5 IU/L), and a 5-day nonstop infusion lost its LH effect in men; but 8 hours a day for 12 days kept LH raised in men, and twice weekly for 8 weeks kept hormones above saline in women (Jayasena et al., 2009; Yeung et al., 2026; Jayasena et al., 2010) |
| It lowers anxiety | Contradicted | In 95 people, a 75-minute infusion didn’t change anxiety scores (p = .13), cortisol, blood pressure or heart rate (Mills et al., 2025) |
| It cuts appetite | Contradicted | Two trials in 27 and 15 healthy men found no change in appetite ratings, brain response to food or food intake after infusions (Yang et al., 2021; Izzi-Engbeaya et al., 2018). No trial followed body weight |
| It stops cancer from spreading | Untested | It was found in melanoma cells and has lab-dish results, and tumor studies are mixed, but we found no trial that gave kisspeptin to people to treat or prevent cancer spread (Lee et al., 1996; Shah et al., 2025; Gomaa et al., 2022) |
| It improves sperm production | Untested | We found no trial that gave kisspeptin to men and measured sperm. The men’s trials measured LH, FSH and testosterone |
| Kisspeptin has no side effects | Mixed | Short trials reported none or mild events, and two ended Takeda trials list no serious ones (Jayasena et al., 2010; Mills et al., 2025; NCT02381288). But the longest dosing we found was 8 weeks, the analogue caused mild events in 26% of healthy subjects, and the FDA flags immunogenicity and impurity risks for compounded kisspeptin-10 (MacLean et al., 2014; FDA, 2026) |
| Kisspeptin vials sold online are pure | Mixed | One analysis of a single black-market kisspeptin-10 vial found no unexpected impurities but more degradation than a reference standard. We found no larger test (Colpaert et al., 2024) |
| It is FDA-approved | Contradicted | No. Drugs@FDA lists no kisspeptin product, and the FDA’s drug-listing data show kisspeptin-10 only as two bulk-ingredient powders (openFDA Drugs@FDA; openFDA NDC) |
| Pharmacies can legally compound it | Contradicted | The FDA placed kisspeptin-10 in category 2 of its 503A list, bulk substances that may present significant safety risks, not in category 1, “under evaluation,” and it isn’t on the 503A bulks list (FDA, 2026; FDA category list, 2026; 21 CFR 216.23) |
| It is banned in sport | Supported | Yes. The World Anti-Doping Agency’s 2026 list names kisspeptin and its agonist analogues under testosterone-stimulating peptides in males, prohibited at all times (WADA, 2026) |
Verdict key. Supported: controlled data in people, or the official record, back it. Mixed: studies disagree, or the support is small or limited to one use. Untested: we found no study in people. Contradicted: the studies or record we found show no effect or the opposite.
What the studies used
| Study | What was tested | Amount and route |
|---|---|---|
| Dhillo et al., 2005 | Hormone response in men | Kisspeptin-54 into a vein, 4 pmol/kg a minute for 90 minutes |
| George et al., 2011 | Hormone response in men | Kisspeptin-10 into a vein: 0.01 to 3.0 mcg/kg single doses; 1.5 or 4 mcg/kg an hour for 22.5 hours |
| Yeung et al., 2026 | Short and repeated use in men | Kisspeptin-10 under the skin by pump: 1.25 to 10 nmol/kg an hour for 8 hours; 180 nmol an hour for 5 days; 150 nmol an hour for 8 hours a day for 12 days |
| Jayasena et al., 2009; Jayasena et al., 2013 | Repeated injections in women | Kisspeptin-54 under the skin, 6.4 nmol/kg twice a day for 1 to 2 weeks |
| Abbara et al., 2015; Abbara et al., 2017 | IVF egg maturation | One kisspeptin-54 injection of 1.6 to 12.8 nmol/kg under the skin; 9.6 nmol/kg plus a second dose 10 hours later |
| Thurston et al., 2022; Mills et al., 2023 | Low sexual desire, brain scans | Kisspeptin-54 into a vein, 1 nmol/kg an hour for 75 minutes |
| Mills et al., 2025 | Hormone response by nasal spray | Kisspeptin-54, 12.8 nmol/kg |
| Abbara et al., 2024 | The analogue MVT-602 | One injection of 0.1 to 3 mcg under the skin |
| MacLean et al., 2014; NCT02381288 | The analogue TAK-448 | 0.01 to 6 mg a day in the first studies; 0.1 mcg daily, 0.3 mcg twice a week or 1 mcg weekly in the low-testosterone trial |
Amounts are given per kilogram, per hour or per dose, and they don’t carry over between kisspeptin-54, kisspeptin-10 and the analogues. Staff gave them in clinics with frequent blood tests. These are amounts from studies, not advice for anyone to use, and none of these trials used a vial bought online.
Side effects and safety
- In the trials. Short studies reported few problems. Women with absent periods who got twice-weekly injections for 8 weeks had no adverse effects observed, a nasal-spray trial reported no adverse events, and the low-desire trial in women reported none (Jayasena et al., 2010; Mills et al., 2025; Thurston et al., 2022).
- IVF. No woman in the 60-woman trial developed moderate, severe or critical OHSS, and in the 62-woman trial moderate OHSS occurred in 0 of 31 with two doses and 1 of 31 with one (Abbara et al., 2015; Abbara et al., 2017).
- The analogues. Mild (grade 1 to 2) adverse events occurred in 26% of healthy subjects on TAK-448 (MacLean et al., 2014). The two ended Takeda trials list no serious adverse events (NCT02381288; NCT02369796). MVT-602 was safe and well tolerated across its dose range (Abbara et al., 2024).
- Hormone effects. Kisspeptin raises LH, FSH and, in men, testosterone, and a continuous analogue lowered testosterone to castration levels. What repeated hormone shifts do over months is not known.
- In rats. Twice-daily kisspeptin-10 injections lowered testosterone and damaged Leydig cells in prepubertal male rats (Ramzan et al., 2022). It is one small animal study, and no human trial has examined the testes.
- The FDA’s concern. For compounded kisspeptin-10 the FDA cites a risk of immunogenicity for certain routes, complexities with peptide-related impurities and characterization, and limited safety information for the proposed routes (FDA, 2026).
- Product quality. One black-market kisspeptin-10 vial was analyzed in 2024: no unexpected impurities, but more degradation than the reference standard (Colpaert et al., 2024).
- Not known. Long-term safety (the longest dosing we found was 8 weeks), safety in pregnancy outside the IVF trigger studies, and effects in children beyond one-time tests. Side effects people report online aren’t covered here; they come from users, not studies.
Legal and approval status
- Not FDA-approved. Drugs@FDA returns no kisspeptin product. The FDA’s drug-listing data include two “Kisspeptin-10 acetate” powders, both listed as bulk ingredients with 2026 start dates and neither a finished drug (openFDA Drugs@FDA; openFDA NDC).
- Compounding. The FDA added kisspeptin-10 to category 2 of its 503A list on September 29, 2023. Category 2 holds bulk substances that may present significant safety risks, and the list was updated May 14, 2026. The 503A bulks list in the regulations holds six other substances (FDA, 2026; FDA category list, 2026; 21 CFR 216.23).
- Not in the HHS policy. The October 2026 temporary policy covers six other peptides (Reuters, 2026).
- Other countries. We did not check how other countries regulate it.
- Research-use vials. Products labeled “research use only” aren’t approved for use in people.
- Sport. The World Anti-Doping Agency’s 2026 list, section S2.2.1, names kisspeptin and its agonist analogues among testosterone-stimulating peptides in males, prohibited at all times. Labs have built urine and blood tests for it (WADA, 2026; Colpaert et al., 2024; Krombholz et al., 2026).
What to look for if you research it
We don’t name or link sellers. These checks come from the studies and from the FDA:
- Which form the claim is about. Kisspeptin-54, kisspeptin-10 and the analogues behave differently: kisspeptin-10 did not raise LH in women in the early follicular phase, and amounts don’t carry across forms (Jayasena et al., 2011).
- Single doses or nonstop dosing. The strongest results are single doses and short infusions. A page that cites them for daily use has skipped the studies where the response faded.
- Hormone results aren’t symptom results. Most trials measured LH and testosterone or brain scans. Only the two low-desire trials measured anything close to how people felt, and each used one infusion.
- Healthy volunteers or patients. Many trials used 3 to 15 healthy volunteers in a clinic. The IVF trials ran in a specialist unit with monitoring.
- The stopped trials. A page that cites testosterone rises without the two Takeda trials that ended early has left out part of the record.
- “No side effects.” Trials were short, and the FDA lists kisspeptin-10 as a compounding ingredient that may present significant safety risks.
Our guide to what to look for explains what each test on a lab report proves and which routes are legal; how to read a peptide study explains how to judge the studies sellers cite.
Trials under way
Four kisspeptin trials we could verify are recruiting, three at Massachusetts General Hospital and one at Imperial College London: see the list, with sponsor, phase, size and registry links.
Already under way: 1 finished with no results posted.
What’s still unknown
- Whether weeks or months of kisspeptin raise testosterone enough in men with low testosterone to change symptoms; the two industry trials of an analogue ended early.
- Whether the brain-scan changes in low-desire trials turn into higher desire in daily life, and whether repeated dosing keeps working.
- How kisspeptin compares with the standard IVF trigger, and live-birth rates against it.
- Long-term safety, what repeated hormone shifts do over months, and whether the Leydig cell damage seen in young rats happens in people.
- What is in vials sold online; we found one analysis of one vial.
- Whether kisspeptin has any effect on cancer in people.
- The results of registered trials still recruiting: sustained dosing for 8 days a month in 76 people, in hypogonadotropic hypogonadism (36), in hypothalamic amenorrhea (20) and a test in post-COVID-19 syndrome (40) (NCT02081924; NCT05896293; NCT07224438; NCT07224490; ClinicalTrials.gov search).
Retracted and flagged studies
A retracted study has been pulled by its journal, usually for serious errors or misconduct, and its results shouldn’t be relied on. A withdrawn paper was pulled, often before final publication. An expression of concern means the journal has flagged a problem it is still looking into.
We check every study this page cites against PubMed and the Retraction Watch database, and search both for flagged studies that mention Kisspeptin. We recheck every month. Last checked Nov 14, 2026.
We found no retracted, withdrawn or flagged studies that mention Kisspeptin.
Studies this page relies on
| Study | Published in | Status |
|---|---|---|
| Lee et al., 1996 | J Natl Cancer Inst | No retraction or concern |
| Dhillo et al., 2005 | J Clin Endocrinol Metab | No retraction or concern |
| Dhillo et al., 2007 | J Clin Endocrinol Metab | No retraction or concern |
| Jayasena et al., 2009 | J Clin Endocrinol Metab | No retraction or concern |
| Jayasena et al., 2010 | Clin Pharmacol Ther | No retraction or concern |
| George et al., 2011 | J Clin Endocrinol Metab | No retraction or concern |
| Jayasena et al., 2011 | J Clin Endocrinol Metab | No retraction or concern |
| George et al., 2013 | Clin Endocrinol (Oxf) | No retraction or concern |
| Jayasena et al., 2013 | J Clin Endocrinol Metab | No retraction or concern |
| Jayasena et al., 2014 | J Clin Endocrinol Metab | No retraction or concern |
| MacLean et al., 2014 | J Clin Endocrinol Metab | No retraction or concern |
| Jayasena et al., 2014 | J Clin Invest | No retraction or concern |
| Abbara et al., 2015 | J Clin Endocrinol Metab | No retraction or concern |
| Clarke et al., 2015 | Endocrinol Metab (Seoul) | No retraction or concern |
| Abbara et al., 2017 | Hum Reprod | No retraction or concern |
| Millar et al., 2017 | J Endocr Soc | No retraction or concern |
| Abbara et al., 2018 | Neuroendocrinology | No retraction or concern |
| Izzi-Engbeaya et al., 2018 | Diabetes Obes Metab | No retraction or concern |
| Ullah et al., 2019 | Andrologia | No retraction or concern |
| Wang et al., 2019 | Clin Exp Pharmacol Physiol | No retraction or concern |
| Romero-Ruiz et al., 2019 | Hum Reprod | No retraction or concern |
| Chan et al., 2020 | J Clin Endocrinol Metab | No retraction or concern |
| Yang et al., 2021 | J Clin Endocrinol Metab | No retraction or concern |
| Abbara et al., 2020 | J Clin Invest | No retraction or concern |
| Abbara et al., 2021 | Neuroendocrinology | No retraction or concern |
| Ramzan et al., 2022 | Protein Pept Lett | No retraction or concern |
| Comninos et al., 2022 | J Clin Endocrinol Metab | No retraction or concern |
| Gomaa et al., 2022 | Asian Pac J Cancer Prev | No retraction or concern |
| Thurston et al., 2022 | JAMA Netw Open | No retraction or concern |
| Mills et al., 2023 | JAMA Netw Open | No retraction or concern |
| Abbara et al., 2024 | Fertil Steril | No retraction or concern |
| Velmurugan et al., 2025 | Curr Med Chem | No retraction or concern |
| Colpaert et al., 2024 | Biomed Chromatogr | No retraction or concern |
| Koysombat et al., 2025 | Physiol Rev | No retraction or concern |
| Galbiati et al., 2025 | Eur J Endocrinol | No retraction or concern |
| Mills et al., 2025 | J Clin Endocrinol Metab | No retraction or concern |
| Mills et al., 2025 | EBioMedicine | No retraction or concern |
| Shah et al., 2025 | Sci Rep | No retraction or concern |
| Galbiati et al., 2026 | J Neuroendocrinol | No retraction or concern |
| Krombholz et al., 2026 | Drug Test Anal | No retraction or concern |
| Naveed et al., 2026 | Hormones (Athens) | No retraction or concern |
| Yeung et al., 2026 | Eur J Endocrinol | No retraction or concern |
| Vasylieva et al., 2026 | Sex Med Rev | No retraction or concern |
| Ramez et al., 2026 | J Sex Med | No retraction or concern |
Bring your questions to other researchers
Our forum opens once 100 researchers join the waitlist. Members post studies, ask what they actually found, and answer with sources.
Questions
What is kisspeptin?
Kisspeptin is a neuropeptide made from the KISS1 gene. It tells the hypothalamus to release GnRH, which sets off LH, FSH and the sex hormones. It isn’t an approved drug (Clarke et al., 2015; openFDA Drugs@FDA).
What does kisspeptin do?
It starts the hormone chain that makes testosterone and estrogen. In trials, single doses raised LH within hours, triggered egg maturation in IVF, and changed brain scans in people with low desire (Dhillo et al., 2005; Jayasena et al., 2014; Mills et al., 2023).
What is kisspeptin-10?
It is the shortest piece of kisspeptin with full activity, 10 amino acids, and the form most used in men’s testosterone studies. The FDA lists it for compounding in its category of ingredients that may present significant safety risks (PubChem CID 25240297; FDA, 2026).
Does kisspeptin increase testosterone?
A single dose or short infusion raised testosterone in men. Nonstop exposure faded: after 5 days LH was back to vehicle levels, and a continuous analogue lowered testosterone to castration levels (George et al., 2011; Yeung et al., 2026; MacLean et al., 2014).
Is kisspeptin-10 for testosterone supported by studies?
Partly. Single doses and 8-hour daily infusions raised LH in healthy men, but we found no trial of weeks of kisspeptin-10 in men with low testosterone, and an analogue trial in that group was ended early (Yeung et al., 2026; NCT02381288).
Kisspeptin-10 or kisspeptin-54: what is the difference?
Kisspeptin-54 is the main natural form, 54 amino acids; kisspeptin-10 is its shortest active piece. Most IVF and brain-scan trials used kisspeptin-54, and most men’s testosterone studies used kisspeptin-10 (Clarke et al., 2015; George et al., 2011).
What are the benefits of kisspeptin peptide?
No benefit has been shown in a way that supports an approved use. The studied uses are triggering egg maturation, raising LH, and low desire, each in small trials (Abbara et al., 2017; Ramez et al., 2026).
What are the side effects of kisspeptin?
Short trials reported none or mild events. The longest dosing we found was 8 weeks, and the FDA cites immunogenicity and impurity risks for compounded kisspeptin-10 (Jayasena et al., 2010; FDA, 2026).
What is the kisspeptin dosage?
We don’t give dosing advice. Trials used 1 nmol/kg an hour for 75 minutes, 1.6 to 12.8 nmol/kg as one IVF injection, and 0.01 to 3.0 mcg/kg doses of kisspeptin-10 in men, all in clinics (Mills et al., 2023; Jayasena et al., 2014; George et al., 2011).
What happens if you take too much kisspeptin?
We found no overdose data. In one trial a 3 mcg/kg dose of kisspeptin-10 gave a smaller LH rise than 1 mcg/kg, so more wasn’t better (George et al., 2011).
Is kisspeptin FDA-approved?
No. Drugs@FDA lists no kisspeptin product, and the FDA places kisspeptin-10 in category 2 of its 503A list (openFDA Drugs@FDA; FDA category list, 2026).
Is kisspeptin banned in sports?
Yes. The World Anti-Doping Agency’s 2026 list names kisspeptin and its agonist analogues among testosterone-stimulating peptides in males, prohibited at all times (WADA, 2026).
Does kisspeptin help fertility or IVF?
In IVF, one kisspeptin-54 injection triggered egg maturation in small trials, but no trial compared it with the standard trigger. In women with absent periods the effect faded with twice-daily dosing (Abbara et al., 2015; Jayasena et al., 2009).
Does kisspeptin increase libido?
Two small single-infusion trials in people with low desire changed brain scans, and in men raised a penile arousal measure. None measured desire over weeks (Thurston et al., 2022; Mills et al., 2023).
Kisspeptin vs PT-141: what is the difference?
They act on different receptors. PT-141 acts on melanocortin receptors and has an approved form for low desire in premenopausal women; kisspeptin acts on KISS1R and has none (Mills et al., 2023).
Can kisspeptin cause weight gain?
We found no trial that followed weight. Infusions didn’t change appetite or food intake in 15 healthy men (Izzi-Engbeaya et al., 2018).
Sources
- Lee JH, et al. KiSS-1, a novel human malignant melanoma metastasis-suppressor gene. J Natl Cancer Inst. 1996;88(23):1731-7. PubMed 8944003
- Clarke H, et al. Comprehensive Review on Kisspeptin and Its Role in Reproductive Disorders. Endocrinol Metab (Seoul). 2015;30(2):124-41. PubMed 26194072
- Dhillo WS, et al. Kisspeptin-54 stimulates the hypothalamic-pituitary gonadal axis in human males. J Clin Endocrinol Metab. 2005;90(12):6609-15. PubMed 16174713
- George JT, et al. Kisspeptin-10 is a potent stimulator of LH and increases pulse frequency in men. J Clin Endocrinol Metab. 2011;96(8):E1228-36. PubMed 21632807
- George JT, et al. Exploring the pathophysiology of hypogonadism in men with type 2 diabetes: kisspeptin-10 stimulates serum testosterone and LH secretion in men with type 2 diabetes and mild biochemical hypogonadism. Clin Endocrinol (Oxf). 2013;79(1):100-4. PubMed 23153270
- Abbara A, et al. Hypothalamic Response to Kisspeptin-54 and Pituitary Response to Gonadotropin-Releasing Hormone Are Preserved in Healthy Older Men. Neuroendocrinology. 2018;106(4):401-410. PubMed 29544222
- Ullah H, et al. Age-dependent changes in the reproductive axis responsiveness to kisspeptin-10 administration in healthy men. Andrologia. 2019;51(4):e13219. PubMed 30590872
- Yeung AC, et al. Chronic subcutaneous kisspeptin-10 stimulates gonadotropin secretion for 12 days in healthy men. Eur J Endocrinol. 2026;195(2):206-216. PubMed 42549827
- Naveed A, et al. Dynamic modulation of LH secretion by continuous kisspeptin infusion in healthy men. Hormones (Athens). 2026. PubMed 42230485
- MacLean DB, et al. Sustained exposure to the investigational Kisspeptin analog, TAK-448, down-regulates testosterone into the castration range in healthy males and in patients with prostate cancer: results from two phase 1 studies. J Clin Endocrinol Metab. 2014;99(8):E1445-53. PubMed 24762108
- Dhillo WS, et al. Kisspeptin-54 stimulates gonadotropin release most potently during the preovulatory phase of the menstrual cycle in women. J Clin Endocrinol Metab. 2007;92(10):3958-66. PubMed 17635940
- Jayasena CN, et al. The effects of kisspeptin-10 on reproductive hormone release show sexual dimorphism in humans. J Clin Endocrinol Metab. 2011;96(12):E1963-72. PubMed 21976724
- Jayasena CN, et al. Subcutaneous injection of kisspeptin-54 acutely stimulates gonadotropin secretion in women with hypothalamic amenorrhea, but chronic administration causes tachyphylaxis. J Clin Endocrinol Metab. 2009;94(11):4315-23. PubMed 19820030
- Jayasena CN, et al. Twice-weekly administration of kisspeptin-54 for 8 weeks stimulates release of reproductive hormones in women with hypothalamic amenorrhea. Clin Pharmacol Ther. 2010;88(6):840-7. PubMed 20980998
- Jayasena CN, et al. Twice-daily subcutaneous injection of kisspeptin-54 does not abolish menstrual cyclicity in healthy female volunteers. J Clin Endocrinol Metab. 2013;98(11):4464-74. PubMed 24030945
- Jayasena CN, et al. Increasing LH pulsatility in women with hypothalamic amenorrhoea using intravenous infusion of Kisspeptin-54. J Clin Endocrinol Metab. 2014;99(6):E953-61. PubMed 24517142
- Romero-Ruiz A, et al. Kisspeptin treatment induces gonadotropic responses and rescues ovulation in a subset of preclinical models and women with polycystic ovary syndrome. Hum Reprod. 2019;34(12):2495-2512. PubMed 31820802
- Millar RP, et al. Hypothalamic-Pituitary-Ovarian Axis Reactivation by Kisspeptin-10 in Hyperprolactinemic Women With Chronic Amenorrhea. J Endocr Soc. 2017;1(11):1362-1371. PubMed 29264460
- Mills EG, et al. Intranasal kisspeptin administration rapidly stimulates gonadotropin release in humans. EBioMedicine. 2025;115:105689. PubMed 40215751
- Jayasena CN, et al. Kisspeptin-54 triggers egg maturation in women undergoing in vitro fertilization. J Clin Invest. 2014;124(8):3667-77. PubMed 25036713
- Abbara A, et al. Efficacy of Kisspeptin-54 to Trigger Oocyte Maturation in Women at High Risk of Ovarian Hyperstimulation Syndrome (OHSS) During In Vitro Fertilization (IVF) Therapy. J Clin Endocrinol Metab. 2015;100(9):3322-31. PubMed 26192876
- Abbara A, et al. A second dose of kisspeptin-54 improves oocyte maturation in women at high risk of ovarian hyperstimulation syndrome: a Phase 2 randomized controlled trial. Hum Reprod. 2017;32(9):1915-1924. PubMed 28854728
- Abbara A, et al. Kisspeptin receptor agonist has therapeutic potential for female reproductive disorders. J Clin Invest. 2020;130(12):6739-6753. PubMed 33196464
- Abbara A, et al. Endocrine profile of the kisspeptin receptor agonist MVT-602 in healthy premenopausal women with and without ovarian stimulation: results from 2 randomized, placebo-controlled clinical tricals. Fertil Steril. 2024;121(1):95-106. PubMed 37925096
- Thurston L, et al. Effects of Kisspeptin Administration in Women With Hypoactive Sexual Desire Disorder: A Randomized Clinical Trial. JAMA Netw Open. 2022;5(10):e2236131. PubMed 36287566
- Mills EG, et al. Effects of Kisspeptin on Sexual Brain Processing and Penile Tumescence in Men With Hypoactive Sexual Desire Disorder: A Randomized Clinical Trial. JAMA Netw Open. 2023;6(2):e2254313. PubMed 36735255
- Mills EG, et al. Kisspeptin Administration Stimulates Reproductive Hormones but Does Not Affect Anxiety in Humans. J Clin Endocrinol Metab. 2025;110(11):3133-3141. PubMed 40036336
- Yang L, et al. The Effects of Kisspeptin on Brain Response to Food Images and Psychometric Parameters of Appetite in Healthy Men. J Clin Endocrinol Metab. 2021;106(4):e1837-e1848. PubMed 33075807
- Izzi-Engbeaya C, et al. The effects of kisspeptin on β-cell function, serum metabolites and appetite in humans. Diabetes Obes Metab. 2018;20(12):2800-2810. PubMed 29974637
- Comninos AN, et al. Acute Effects of Kisspeptin Administration on Bone Metabolism in Healthy Men. J Clin Endocrinol Metab. 2022;107(6):1529-1540. PubMed 35244717
- Galbiati F, et al. Sex-dependent increases in oxytocin levels in response to intravenous kisspeptin in humans. Eur J Endocrinol. 2025;192(3):K24-K29. PubMed 39965102
- Galbiati F, et al. Intravenous kisspeptin 112-121 bolus does not acutely impact circulating vasopressin in humans. J Neuroendocrinol. 2026;38(1):e70114. PubMed 41273106
- Abbara A, et al. Kisspeptin-54 Accurately Identifies Hypothalamic Gonadotropin-Releasing Hormone Neuronal Dysfunction in Men with Congenital Hypogonadotropic Hypogonadism. Neuroendocrinology. 2021;111(12):1176-1186. PubMed 33227799
- Chan YM, et al. Using Kisspeptin to Predict Pubertal Outcomes for Youth With Pubertal Delay. J Clin Endocrinol Metab. 2020;105(8):e2717-25. PubMed 32232399
- Shah H, et al. Exogenous kisspeptin-10 treatment shows pleiotropy via induction of KISS1 expression, metastasis suppression, and promotes apoptosis in triple-negative breast cancer. Sci Rep. 2025;15(1):35182. PubMed 41062590
- Wang XQ, et al. Low KISS1 expression predicts poor prognosis for patients with colorectal cancer: A meta-analysis. Clin Exp Pharmacol Physiol. 2019;46(7):625-634. PubMed 30932210
- Gomaa SH, et al. Evaluation of KISS1 Receptor Gene Expression in Egyptian Female Patients with Breast Cancer. Asian Pac J Cancer Prev. 2022;23(3):961-969. PubMed 35345369
- Koysombat K, et al. Kisspeptin and neurokinin B: roles in reproductive health. Physiol Rev. 2025;105(2):707-764. PubMed 39813600
- Ramez M, et al. Peptides for male sexual dysfunction: a systematic review of emerging evidence. J Sex Med. 2026;23(12):qdag338. PubMed 43002584
- Vasylieva V, et al. Peptides in urology and sexual medicine: clinical effectiveness, dosing, indications, and safety: a narrative review. Sex Med Rev. 2026;14(4):qeag078. PubMed 42862021
- Velmurugan H, et al. Kisspeptin and its Current Clinical Status-A Systematic Review. Curr Med Chem. 2025;32(7):1313-1322. PubMed 38265397
- Colpaert T, et al. Investigating the detection of the novel doping‐relevant peptide kisspeptin‐10 in urine using liquid chromatography high‐resolution mass spectrometry. Biomed Chromatogr. 2024;38(9):e5946. PubMed 38978171
- Krombholz S, et al. Analysis and Characterization of Kisspeptin and Its Analogues in Serum and Urine Samples by Liquid Chromatography-High-Resolution Mass Spectrometry for Doping Control Purposes. Drug Test Anal. 2026;18(7):862-876. PubMed 42057309
- Ramzan F, et al. Dose-Dependent Degeneration of Leydig Cells Following Kisspeptin-10 Administration: An Ultrastructural Study. Protein Pept Lett. 2022;29(1):64-70. PubMed 34961438
- ClinicalTrials.gov. Records NCT02381288, NCT02369796, NCT01667406, NCT02081924, NCT05896293, NCT07224438 and NCT07224490, November 14, 2026. Search
- U.S. Food and Drug Administration. Global Substance Registration System: Kisspeptin-10 (UNII FS1N52VS3S). GSRS
- U.S. Food and Drug Administration. Safety risks associated with certain bulk drug substances nominated for use in compounding. Content current as of April 22, 2026. FDA page
- U.S. Food and Drug Administration. Bulk drug substances nominated for use in compounding under section 503A: categories, updated May 14, 2026 (kisspeptin-10 in category 2). FDA document
- U.S. Food and Drug Administration. openFDA Drugs@FDA: search for kisspeptin, November 14, 2026 (no match). openFDA
- U.S. Food and Drug Administration. openFDA drug listings (NDC): two listings of kisspeptin-10 acetate as a bulk ingredient, November 14, 2026. openFDA NDC
- Code of Federal Regulations. 21 CFR 216.23, Bulk drug substances that can be used to compound drug products in accordance with section 503A, as of November 1, 2026. eCFR
- World Anti-Doping Agency. 2026 Prohibited List, section S2.2.1 (testosterone-stimulating peptides in males, including kisspeptin and its agonist analogues). WADA document
- Reuters. U.S. health department to allow temporary sale of some unapproved peptides. October 28, 2026. Article
- National Library of Medicine. PubChem compound record: Kisspeptin-10 (KP-10, metastin 45-54) (CID 25240297). PubChem
Last reviewed Nov 14, 2026. Approval and compounding status change often; we recheck this page when they do. Nothing here is medical advice; see our medical disclaimer. Found a mistake? Email editors@peptideresearchstudy.com.